Related Experiment Video

Updated: Jun 27, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?

Simon K Winn1, Sarah Ellis, Philip Savage

  • 1Department of Renal Medicine, St Helier Hospital, Carshalton, Surrey SM5 1AA, UK. simon.winn@epsom-sthelier.nhs.uk

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
|November 29, 2008
PubMed

Insights

Tyrosine kinase inhibitors (TKIs) like Sunitinib are standard for renal cancer but can rarely cause acute interstitial nephritis. This report details the first biopsy-confirmed case, suggesting TKIs may pose a risk for this kidney complication.

Area of Science:

  • Nephrology
  • Oncology
  • Pharmacology

Background:

  • Tyrosine kinase inhibitors (TKIs), including Sunitinib and Sorafenib, are widely used in metastatic renal cell cancer treatment since 2006.
  • These targeted therapies are generally well-tolerated with low reported renal toxicity.

Observation:

  • A case of acute interstitial nephritis (AIN) was confirmed via biopsy in a patient undergoing Sunitinib treatment for metastatic renal cell cancer.
  • This represents the first biopsy-proven instance of AIN linked to Sunitinib therapy.

Findings:

  • The occurrence of AIN in this patient, alongside two prior TKI-associated AIN reports, suggests a potential link between TKI therapy and AIN.
  • This highlights a rare but serious adverse event associated with TKI use in renal cancer.

Implications:

  • Clinicians should be aware of the potential for TKI-induced acute interstitial nephritis, even when renal toxicity is not typically expected.
  • Prompt recognition and management of AIN are crucial for patients receiving TKI therapy to prevent severe renal complications.
  • Further investigation into the mechanisms and incidence of TKI-associated AIN is warranted.

More Related Videos

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...